<DOC>
	<DOCNO>NCT00606268</DOCNO>
	<brief_summary>The study evaluate PK safety two dose level Micafungin ( FK463 ) Antifungal prophylaxis child adolescent undergo HSCT</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Repeated Dose Micafungin Antifungal Prophylaxis Children Adolescents Who Undergo Hematopoietic Stem Cell Transplant</brief_title>
	<detailed_description>This prospective , multi-center , open-label , repeat-dose pharmacokinetic study contain two treatment ( micafungin 1.0mg/kg 1.5mg/kg ) dose group . Subjects enrol accord age stratify weight receive either 1.0mg/kg ( weight &gt; 25kg ) 1.5mg/kg ( weight &lt; 25kg ) micafungin . Children ( 4 month &lt; 2years , 2 5 year 6 11 year ) adolescent ( 12 16 year ) undergo HSCT require antifungal prophylaxis enrol</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Institutional Review Board ( IRB ) approve write informed Consent / Assent ( applicable ) HIPAA Authorization must obtain subject ( able ) /or subject 's parent/legally authorize representative prior studyrelated procedure Subject sufficient venous access permit administration study drug , collect pharmacokinetic sample monitor laboratory safety variable Female subject childbearing potential must negative pregnancy test within 72 hour prior first dose study drug , sexually active agree method birth control per Investigator judgment duration study Subject ( able ) /or subject parent/legally authorize representative agree comply study requirement concomitant medication restriction Subject plan undergo HSCT Subject evidence significant liver disease define aspartate transamine ( AST/SGOT ) , alanine transaminase ( ALT/SGPT ) 10 time upper limit normal ( ULN ) total bilirubin alkaline phosphatase &gt; 5 time ULN Subject concomitant medical condition opinion Investigator /or medical monitor precludes enrollment study Subject evidence active systemic disseminate fungal infection prior enrollment Subject history anaphylaxis , hypersensitivity , serious reaction echinocandin class antifungal Subject receive treatment echinocandin within one week prior first dose study drug Subject status unstable subject unlikely complete require study procedure Female subject pregnant nursing . Females childbearing potential must avoid become pregnant receiving study drug</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Antifungal Prophylaxis</keyword>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>HSCT</keyword>
	<keyword>Micafungin</keyword>
</DOC>